<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01825031</url>
  </required_header>
  <id_info>
    <org_study_id>ISRCTN43622374</org_study_id>
    <nct_id>NCT01825031</nct_id>
  </id_info>
  <brief_title>Reduction of EArly mortaLITY in HIV-infected Adults and Children Starting Antiretroviral Therapy</brief_title>
  <acronym>REALITY</acronym>
  <official_title>Reduction of Early mortALITY in HIV-infected African Adults and Children Starting Antiretroviral Therapy: a Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anna Griffiths, MRC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Department for International Development, United Kingdom</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medical Research Council</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PENTA Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Medical Research Council</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomised controlled trial to investigate three methods to reduce early mortality in&#xD;
      adults, adolescents and children aged 5 years or older starting antiretroviral therapy (ART)&#xD;
      with severe immuno-deficiency. The three methods are:&#xD;
&#xD;
      (i) increasing the potency of ART with a 12 week induction period using 4 antiretroviral&#xD;
      drugs from 3 classes&#xD;
&#xD;
      (ii) augmented prophylaxis against opportunistic/bacterial infections and helminths for 12&#xD;
      weeks&#xD;
&#xD;
      (iii) macronutrient intervention using ready-to-use supplementary food for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      REALITY is a open-label randomised trial of 1800 adults, adolescents and children aged 5&#xD;
      years or more with low CD4 counts about to initiate ART.&#xD;
&#xD;
      The trial will have a factorial design with 3 randomisations, each to address one of the&#xD;
      potential approaches to reduce early mortality in adults and children initiating ART with low&#xD;
      CD4, namely:&#xD;
&#xD;
        1. Raltegravir for 12 weeks from ART initiation in addition to 3 standard ART (3-drug&#xD;
           2-class) versus standard of care first-line 3-drug 2-class ART (choice according to&#xD;
           national guidelines for ART initiation);&#xD;
&#xD;
        2. Immediate enhanced opportunistic infections (OI) prophylaxis with isoniazid/pyridoxine&#xD;
           and cotrimoxazole, plus 12 weeks fluconazole, 5 days azithromycin and a single dose of&#xD;
           albendazole versus cotrimoxazole prophylaxis alone for the first 12 weeks followed by&#xD;
           isoniazid and any prophylaxis and/or treatment prescribed at screening&#xD;
&#xD;
        3. supplementation with Ready to Use Supplementary Food (RUSF) for 12 weeks versus standard&#xD;
           of care nutritional support to those with poor nutritional status according to local&#xD;
           guidelines.&#xD;
&#xD;
      All participants will receive cotrimoxazole throughout the trial.&#xD;
&#xD;
      The primary objective of the trial is to identify effective, safe and acceptable&#xD;
      interventions to reduce early mortality (all-cause) in HIV-infected adults, adolescents, and&#xD;
      older children (5 years or more) initiating ART.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>All-cause mortality over the first 24 weeks after starting ART</measure>
    <time_frame>Week 24</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>48 week mortality (all-cause)</measure>
    <time_frame>Week 48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>Week 0-48</time_frame>
    <description>serious adverse events&#xD;
grade 4 adverse events&#xD;
adverse events leading to modification of ART or other study drugs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital inpatient episodes and total days admitted</measure>
    <time_frame>Week 0-48</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to ART and acceptability of each strategy</measure>
    <time_frame>Week 0-48</time_frame>
    <description>Adherence to ART, OI drugs and RUSF will be assessed in all participants at each visit by pill counts and short nurse-administered questions. Every 12 weeks, a more detailed adherence questionnaire will be adminstered.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint relating to anti-infection intervention</measure>
    <time_frame>0-48 weeks</time_frame>
    <description>Incidence of tuberculosis (TB), cryptococcal and candida disease, severe bacterial infections</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint relating to anti-malnutrition intervention</measure>
    <time_frame>0-48 weeks</time_frame>
    <description>BMI, weight and body fat assessed by bioimpedance analysis (BIA), height (in children) and grip strength</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endpoint relating to anti-HIV intervention</measure>
    <time_frame>0-48 weeks</time_frame>
    <description>Changes in CD4 cell count</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">1805</enrollment>
  <condition>Human Immunodeficiency Virus</condition>
  <arm_group>
    <arm_group_label>Antiretroviral Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Raltegravir twice daily for 12 weeks from antiretroviral therapy (ART) initiation in addition to 3 standard ARVs (2NRTIs/1NNRTI) compared with 3 standard ARVs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Opportunistic Infection (OI) Prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immediate isoniazid/pyridoxine and cotrimoxazole, plus 12 weeks fluconazole, 5 days azithromycin and a single dose of albendazole compared with immediate cotrimoxazole (if not already taking this) in all patients plus (not malawi)isoniazid/pyridoxine after 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nutritional Support</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Supplementation with Ready to Use Supplementary Food (RUSF) for 12 weeks compared with supplementation for those with severe malnutrition as local practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Raltegravir</intervention_name>
    <description>400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs</description>
    <arm_group_label>Antiretroviral Therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>100mg once daily for 12 weeks</description>
    <arm_group_label>Opportunistic Infection (OI) Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>500mg once daily for 5 days</description>
    <arm_group_label>Opportunistic Infection (OI) Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albendazole</intervention_name>
    <description>a single dose 400mg</description>
    <arm_group_label>Opportunistic Infection (OI) Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>300mg taken immediately in combination with cotrimoxazole</description>
    <arm_group_label>Opportunistic Infection (OI) Prophylaxis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Ready to Use Supplementary Food</intervention_name>
    <description>2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks</description>
    <arm_group_label>Nutritional Support</arm_group_label>
    <other_name>RUSF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 5 years or older&#xD;
&#xD;
          -  Documented HIV infection by HIV ELISA or HIV rapid test&#xD;
&#xD;
          -  Naive to ART&#xD;
&#xD;
          -  CD4 T-cell count &lt;100 cells/mm3 on blood test taken at screening for REALITY&#xD;
&#xD;
          -  Results of screening haematology and biochemistry tests available and no&#xD;
             contraindications to planned ART according to national guidelines&#xD;
&#xD;
          -  Patient/carer provide informed consent (and children &lt;18 years assent, as appropriate&#xD;
             according to their age and knowledge of HIV status)&#xD;
&#xD;
        The lower age limit is because CD4 counts are less reliable predictors of immunodeficiency&#xD;
        under 5 years: CD4 counts are recommended by guidelines in older children.&#xD;
&#xD;
        No patient with a CD4 count above 100 cells/mm3 should have ART delayed in order to&#xD;
        subsequently meet eligibility criteria. Rather, patients eligible for REALITY will be those&#xD;
        testing HIV positive for the first time with a low CD4 count (i.e. those delaying&#xD;
        presentation to care), or those who have defaulted before initiating ART and only return to&#xD;
        care at an advanced stage of immuno-deficiency.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Contraindications to any proposed antiretroviral drugs (including integrase&#xD;
             inhibitors), isoniazid, fluconazole, albendazole or azithromycin&#xD;
&#xD;
          -  Pregnant or breastfeeding or intending to become pregnant during the first 12 weeks of&#xD;
             the study&#xD;
&#xD;
          -  Ever known to have previously received single-dose nevirapine for prevention of&#xD;
             mother-to-child transmission (mother or child).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diana M Gibb</last_name>
    <role>Study Director</role>
    <affiliation>Medical Research Council</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Moi University Clinical Research Centre</name>
      <address>
        <city>Eldoret</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KEMRI Wellcome Trust Research Programme</name>
      <address>
        <city>Kilifi</city>
        <country>Kenya</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Malawi</name>
      <address>
        <city>Blantyre</city>
        <country>Malawi</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre, Fort Portal</name>
      <address>
        <city>Fort Portal</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre, Gulu</name>
      <address>
        <city>Gulu</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre, Mbale</name>
      <address>
        <city>Mbale</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Clinical Research Centre, Mbarara</name>
      <address>
        <city>Mbarara</city>
        <country>Uganda</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Zimbabwe Clinical Research Centre</name>
      <address>
        <city>Harare</city>
        <country>Zimbabwe</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kenya</country>
    <country>Malawi</country>
    <country>Uganda</country>
    <country>Zimbabwe</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <study_first_submitted>January 7, 2013</study_first_submitted>
  <study_first_submitted_qc>April 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2013</study_first_posted>
  <last_update_submitted>April 19, 2016</last_update_submitted>
  <last_update_submitted_qc>April 19, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 20, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical Research Council</investigator_affiliation>
    <investigator_full_name>Anna Griffiths, MRC</investigator_full_name>
    <investigator_title>Trial Manager</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Isoniazid</mesh_term>
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Albendazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

